Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, the pi4kβ1β2 double mutant in Arabidopsis thaliana exhibited altered root growth, increased susceptibility to Blumeria graminis, and a potential correlation between PI4K activity and auxin response and immunity due to changes in vesicular trafficking and actin filaments.

This study highlights that hydrogel formulations unexpectedly prolonged healing in trials, pointing to a need for design based on detailed pathophysiological insights rather than empirical methods, and suggests technologies like AI materials optimization and 3D bioprinting to aid their clinical use for cancer survivors.

This study found that the transcription factor CAP1 negatively regulates KRT83 expression in Tan sheep, possibly influencing their curly hair phenotype.

This study found that ionizing radiation primarily affects keratinocyte stem cells in the hair follicle, suggesting they play a central role in radiation-induced hair graying, rather than melanocyte stem cells.

This paper discusses the recent online debate over the use of PRP in hair restoration but provides no new findings.

This study found that a microneedle system delivering VEGF and Ritlecitinib improved hair regeneration in mice with androgenetic alopecia, showing faster anagen onset and better hair quality compared to minoxidil.

This review synthesizes current evidence on platelet-rich plasma for dry eye disease and reports no new results; the authors emphasize the need for standardized trials to validate these approaches.

This study observed that most patients with alopecia areata experienced sustained scalp hair regrowth after 48 weeks of ritlecitinib treatment, with safety consistent with prior findings.

EGFR cancer drugs often cause a rash, which can lead to distress and isolation, but may also improve outcomes for some cancer patients. Current treatments for the rash are limited, but a compound called menadione shows promise.

This study found that modeling and simulation effectively informed decision-making and dose selection for ritlecitinib in treating alopecia areata, supporting an accelerated drug development strategy.

This review summarized the latest knowledge suggesting that Janus kinase inhibitors may have therapeutic potential for treating skin diseases like atopic dermatitis and psoriasis, especially when conventional therapies do not work.

ITK inhibitors may effectively treat alopecia areata.

In this study, hibiscus leaf extract hair tonic at 10% concentration showed better hair growth promotion activity compared to minoxidil 2% in a rabbit model, although it caused eye irritation.

This study introduced the dual-flow-RootChip platform to demonstrate that Arabidopsis roots exhibit non-autonomous adaptations, such as hair growth regulation, when subjected to varied environmental conditions on opposite sides.

This study reported that a newly developed hydrogel patch, designed to recruit regulatory T cells through ROS-triggered release of CCL22, improved wound healing and hair follicle regeneration in a diabetic mouse model by scavenging ROS, thereby protecting Tregs and suppressing Th17 cells.

This study found that a 10% hibiscus leaf extract hair tonic demonstrated better hair growth activity than 2% minoxidil in rabbits but caused eye irritation.

This study found that treatment with ritlecitinib improved hair regrowth in alopecia areata patients, with many achieving significant results after 24 weeks compared to placebo.

In this study, researchers found that ritlecitinib 50 mg offered a lower cost per responder than baricitinib 2 or 4 mg at both 24 and 52 weeks for treating severe alopecia areata, suggesting potential implications for reimbursement or formulary decisions.

In this study, researchers found that the loss of SETDB1 in epidermal keratinocytes led to altered chromatin states, increased ERV expression, and activation of immune responses, while inhibiting these effects with certain antiviral drugs reduced skin inflammation and hair loss in a mouse model.

In an animal study, researchers found that a hair tonic containing a 1:1 ratio of kelor and rambutan leaf extracts led to similar hair growth in rabbits compared to a minoxidil control, with average hair lengths of 3 cm versus 2.025 cm, respectively.

The trial is ongoing, but researchers are evaluating the efficacy and safety of REZPEG, a potential new therapy for severe alopecia areata, which selectively expands regulatory T cells.

This study reports that JAK inhibitors were effective in inducing remission in ulcerative colitis patients and presented an acceptable safety profile with a range of manageable side effects.

This study reports that improvements to the EczemaNet pipeline, incorporating pixel-level segmentation and data augmentation, enhanced the reliability and interpretability of assessing atopic dermatitis severity from digital images.

This study observed that both ritlecitinib and brepocitinib improved scalp biomarkers in patients with alopecia areata, with associations to hair regrowth seen in this phase 2a trial.

This article describes a method using the CUBIC protocol to clarify and visualize molecular and cellular interactions in mouse skin biopsies at single cell resolution, but does not provide new biological findings.

This study introduced and validated the VESALT, a visual extension of the Severity of Alopecia Tool, finding it offers improved reliability and user-friendliness over SALT by incorporating pattern recognition and broader coverage, including non-scalp regions, in assessing alopecia areata severity.

In this study, gel containing apigenin and celery herb extract was observed to effectively stimulate hair growth and did not cause skin irritation in male Sprague-Dawley rats.

This study found that treatment with ritlecitinib led to significant scalp hair regrowth in patients with alopecia areata at Weeks 24 and 48, with higher response rates observed in those receiving 50 mg compared to 30 mg doses.

In this study, researchers found that ritlecitinib, a JAK3/TEC inhibitor, significantly improves hair regrowth, quality of life, and psychological well-being in patients with severe alopecia areata who had inadequate or no response to baricitinib, a JAK1/2 inhibitor.